Amgen and Kyowa Kirin’s anti-OX40 antibody rocatinlimab vindicated itself this weekend, with new Phase III data pointing to its strong efficacy in moderate to severe atopic dermatitis. These findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback